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Douglas R. Fullen3, Monique E. Verhaegen2, Timothy M. Johnson2, Andrzej A. Dlugosz2 and Theodora S. Ross1
Merkel cell carcinoma (MCC) is a neoplasm thought to originate from the neuroendocrine Merkel cells of the
skin. Although the prevalence of MCC has been increasing, treatments for this disease remain limited because
of a paucity of information regarding MCC biology. We have found that the endocytic oncoprotein Huntingtin-
interacting protein 1 (HIP1) is expressed at high levels in B90% of MCC tumors and serves as a more reliable
histological cytoplasmic stain than the gold standard, cytokeratin 20. Furthermore, high anti-HIP1 antibody
reactivity in the sera of a cohort of MCC patients predicts the presence of metastases. Another protein that is
frequently expressed at high levels in MCC tumors is the stem cell factor (SCF) receptor tyrosine kinase, c-Kit.
In working toward an understanding of how HIP1 might contribute to MCC tumorigenesis, we have discovered
that HIP1 interacts with SCF-activated c-Kit. These data not only identify HIP1 as a molecular marker for
management of MCC patients but also show that HIP1 interacts with and slows the degradation of c-Kit.
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INTRODUCTION
Merkel cell carcinoma (MCC) is an aggressive skin cancer
thought to be derived from the sensory Merkel cells of the
skin (Bichakjian et al., 2007). Although the overall incidence
of this disease is low and affects B1400 patients per year in
the United States, this cancer is associated with a poor
prognosis, and most patients with metastatic disease do not
survive more than 5 years (Bichakjian et al., 2007). Clinical
management of patients with MCC is limited because of a
lack of prognostic markers and effective therapies. These
limitations stem from a lack of understanding of the biology
of MCC’s initiation, maintenance, and progression to the
metastatic stage. Currently, surgical excision of the primary
tumor and radiation remain the main therapeutics for MCC
(Bichakjian et al., 2007).
Although receptor tyrosine kinases (RTKs), such as c-Kit,
have been shown to be increased in expression in MCC,
convincing clinical data regarding the effectiveness of
specific c-Kit inhibitors, such as imatinib, on patient survival
are not yet available (Lemos and Nghiem, 2007). Recently, a
virus designated as Merkel cell polyoma virus has been found
in tumors from MCC patients but not their normal skin tissue
(Feng et al., 2008). In contrast, its use as a serum biomarker is
not clear because of limited specificity. Antibodies against
the virus have been found in a large number of tumor-free
individuals as well (Carter et al., 2009). Furthermore, its role
in initiating MCC remains hypothetical (Gandhi et al., 2009).
A better understanding of how c-Kit or Merkel cell polyoma
virus contributes to the induction, maintenance, and progres-
sion of MCC will facilitate the development of effective
therapies.
Huntingtin-interacting protein 1 (HIP1) is a highly
conserved protein that interacts with components of
the endocytic machinery, including 3-phosphoinositides,
clathrin, and the AP2 adaptor complex (Engqvist-Goldstein
et al., 1999, 2001; Metzler et al., 2001; Mishra et al.,
2001; Rao et al., 2001; Waelter et al., 2001; Hyun and Ross,
2004). All of these molecules are involved in the clathrin-
mediated internalization of surface receptors. Unlike AP2
(Mitsunari et al., 2005), HIP1 is not necessary for embry-
ogenesis or early postnatal development, but young adult
mice deficient for HIP1 do develop a degenerative phenotype
(Oravecz-Wilson et al., 2004). In addition, HIP1 overexpres-
sion transforms fibroblasts (Rao et al., 2003) and prostate
epithelial cells (Wang et al., 2008), and HIP1 transgenic mice
develop plasma cell neoplasms (Bradley et al., 2007b).
In addition to its transforming activity, high HIP1 expres-
sion is associated with a variety of human cancers, including
prostate, colon, breast, brain, and lymphoid cancers
(Rao et al., 2002, 2003; Bradley et al., 2007a, b). HIP1
expression in prostate tumors is associated with a poor
prognosis, suggesting that HIP1 overexpression may func-
tionally promote tumorigenesis (Bradley et al., 2005).
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Anti-HIP1 antibodies have been detected in the sera of
patients with prostate, lymphoid, and brain cancers more
frequently than in the sera of cancer-free individuals (Bradley
et al., 2005, 2007a, b). These findings indicate that testing for
anti-HIP1 antibodies in serum may serve as a useful non-
invasive test to detect the presence, recurrence, or progres-
sion of some human tumors.
Further investigation into the role of HIP1 in tumorigenesis
has demonstrated an association between the presence of this
oncoprotein and enhanced RTK expression (Rao et al., 2003;
Bradley et al., 2007a). These findings are not unexpected
because of the association of HIP1 with components of the
clathrin-mediated endocytosis pathway, which is a mechan-
ism for modulation of receptor levels. Indeed, not only is
HIP1 overexpression in tumors associated with the over-
expression of RTKs, but HIP1-mediated transformation also
can be blocked with tyrosine kinase inhibitors (Rao et al.,
2003). We have found that coexpression of HIP1 with EGFR
increases the half-life of EGFR upon EGF stimulation (Hyun
et al., 2004) and that HIP1 physically associates with EGFR
(Bradley et al., 2007a). Others have found that HIP1 also
stabilizes and associates with the fibroblast growth factor
receptor 4 (Wang et al., 2008). These interactions together
with HIP1’s overexpression in multiple cancers suggest that
HIP1-mediated transformation may occur via concomitant
increases in multiple RTK signals.
The potential of HIP1 as a clinical marker for several
types of tumors, along with its high expression in neural crest-
derived peripheral neurons (Rao et al., 2002), led us to
examine the possibility that HIP1 could serve as a marker for
MCC. We evaluated a large series of MCC tissue samples and
found vastly elevated HIP1 protein levels compared with
normal surrounding skin tissue. We also detected high levels
of anti-HIP1 antibodies in sera from a separate cohort of MCC
patients. Some of the patients with metastatic MCC exhibited
higher levels of anti-HIP1 antibodies compared with MCC
patients with localized disease. Furthermore, in an effort to
discover how HIP1 expression may functionally contribute to
MCC biology, we discovered that HIP1 physically associates
with and stabilizes c-Kit, a RTK specifically expressed at high
levels in MCC (Su et al., 2002; Sattler and Salgia, 2004).
RESULTS
MCC specimens demonstrate high levels of HIP1 staining
To evaluate HIP1 as a possible MCC marker, paraffin-
embedded tissue samples from MCC tumors and the similar
‘‘round blue cell’’ neuroendocrine tumors, small-cell lung
cancer (SCLC), were immunostained for HIP1 expression
(Figure 1a). These tumors were evaluated for both HIP1
expression level and cellular localization. HIP1 is not
expressed at high levels in normal skin with the exception
of vascular endothelium (Rao et al., 2002). Tumor tissue was
visually scored for HIP1 expression on a scale of 0–3, in
which a score of 3 represented the highest HIP1 staining
and a score of 0 indicated a lack of staining (Bradley et al.,
2007b).
In all, 89% (n¼25/28) of MCC tissue samples in our first
MCC patient cohort exhibited high HIP1 expression (Table 1).
MCC tissue samples displayed both diffuse cytoplasmic
staining as well as perinuclear dot patterns of staining. HIP1
expression occurred much more frequently in MCC tumors
than in SCLC tumors (n¼5/12 for SCLC; 42%). In particular,
frequency of HIP1 overexpression was significantly higher in
metastatic MCC as compared with metastatic SCLC (Table 1).
This finding is clinically significant, as MCC and SCLC
are often difficult to distinguish from one another in the
metastatic setting.
Additionally, as one would predict with increased HIP1
protein expression in MCC tumors, using mRNA microarrays
and a distinct cohort of patients, a 6-fold average increase in
HIP1 transcript was detected in MCC tumors. A cohort of 30
patients was studied and 29 of them displayed an elevated
HIP1 transcript compared with squamous cell carcinomas.
High HIP1 levels have not been observed in squamous
cell carcinomas (Rao et al., 2002). In contrast to HIP1, HIP1
related, only known mammalian relative of HIP1, was
not elevated at the mRNA level (personal communication,
Paul Harms, University of Michigan).
We also compared HIP1 tumor staining with the known
MCC markers, cytokeratin 20 (CK20) and c-Kit (Figure 1b).
A separate cohort of 14 MCC tumors from archived samples
from MCC patients (all of whose diagnoses were based on
immunophenotyping and clinicopathological correlations at
the University of Michigan) was used for generation of a
tissue microarray (TMA) to compare HIP1, CK20, and c-Kit.
Each tumor was represented by three different spots on
the TMA slide for purposes of better tumor coverage. As is
evident in the top row, HIP1 staining for MCC was very
strong, diffuse, and sensitive (100% positive; n¼14/14). In
comparison, CK20 staining was less reliable and positive in
only 64% of the tumor samples (third row versus the top row;
n¼9/14). This frequency of CK20 staining is lower than
previous reports where it has been found to be positive in
B80% of MCC tumors. This also does not reflect the original
pathological assessment for each of the tumors from which
they were derived, as 13 of the 14 were reported as positive
for CK20 staining. This difference is likely due to the use of a
TMA rather than the entire slide for testing each tumor. As
CK20 staining is not as uniformly distributed in the tumor
cells as HIP1 staining is, it is possible that a positive tumor
could test falsely negative for CK20 because of there being
less tissue represented on a TMA. These data nevertheless
indicate that the chance of misdiagnosing an MCC when
staining for CK20 is greater than when staining for HIP1.
As the HIP1 antibody stained every tumor, the HIP1 test was
positive in all tumors that tested positive for CK20 (third
row versus top row) and another important MCC marker c-Kit
(second row versus top row).
HIP1 does not affect the development or maintenance of
normal Merkel cells
To determine whether HIP1 is necessary for the development
of normal Merkel cells, we analyzed the skin of wild-type and
HIP1-null mice (Oravecz-Wilson et al., 2004). Anti-CK20
antibodies were used to identify mature Merkel cells in the
mouse tail skin and vibrissae, locations where Merkel cells
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generally congregate around hair follicles. No visible
changes in the abundance of mature Merkel cells were
observed in the HIP1-null mouse skin as compared with
wild-type littermate skin (Figure 1c). These data indicate that
HIP1 is not required for the development or maintenance
of normal Merkel cells.
MCC patients harbor anti-HIP1 autoantibodies in their blood
To detect the presence of anti-HIP1 antibodies in MCC
patient blood, patient sera were tested for immune
reactivity to HIP1 antigens as described previously (Bradley
et al., 2005). Initially, serum samples were screened against
the previously described carboxyl-terminal HIP1 recombi-
nant antigen (Bradley et al., 2005, 2007a, b). In all, 85%
of MCC patients (n¼34/40) displayed the presence of
autoantibodies (Supplementary Figures S1A and S2 online).
This frequency was similar to that previously found in
patients with glioblastoma multiforme (Bradley et al.,
2007a). This high antibody prevalence and the elderly nature
of this population (Table 2) raised the question of whether the
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Figure 1. Huntingtin-interacting protein 1 (HIP1) is expressed at high levels in primary Merkel cell carcinoma (MCC) but not in small-cell lung cancer (SCLC),
and is not required for normal Merkel cells. (a) Example of HIP1 staining in MCC compared with SCLC tumors. Bar¼ 50 mm. (b) Three representative patient
tumors co-immunostained for HIP1 (UM4B10), c-Kit, cytokeratin 20 (CK20), and hematoxylin and eosin (Hþ E). These tumors were selected from an MCC tissue
microarray that contained 42 MCC spots from 14 patients. (c) CK20 staining of Merkel cells in wild-type and Hip1null/null
(Oravecz-Wilson et al., 2004) mouse tail skin and vibrissae. Bar¼ 50mm.
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humoral response was the result of coexistence of other types
of tumors with elevated HIP1 levels. We found that there
were many coexisting basal and squamous cell carcinomas
in this patient cohort but very few other tumors. There was no
correlation of a humoral response with previous cancer
diagnoses (Supplemental Table SI online). The high degree of
HIP1 seropositivity to this antigen also made intergroup
comparisons difficult; hence, in the interest of improving the
specificity of the test, patient sera were also tested for
reactivity against a different HIP1 recombinant antigen that
encoded the amino terminus. This antigen contains the lipid-
binding (AP180 N-terminal homology), clathrin-binding, and
AP2-binding domains (Supplementary Figure S1C online).
Only 30% of MCC patients (n¼12/40) harbored antibodies
against the HIP1 N-terminal antigen (Supplementary Figure
S1A and B online). This frequency was low enough to make
possible clinical correlations between patients that were
positive or negative for these antibodies (see below).
Sera from patients with metastatic MCC exhibited high
antibody reactivity to the HIP1 N terminus
To examine the possibility that anti-N-terminal HIP1 anti-
bodies in MCC patient sera could correlate with a biological
outcome, the humoral response to the N terminus of HIP1 in
MCC patients were compared with a number of clinical
parameters. These parameters included tumor size, disease
status at time of blood draw, presence of metastasis at time of
blood draw, past (or concurrent) other cancer diagnoses
(Supplemental Table SI online), survival of 2.5 years after
blood draw, age, and gender. Of these parameters, only the
presence of metastasis and female gender displayed a
significant association with high serum reactivity to HIP1.
Patients with metastatic MCC tested positive for elevated
anti-N-terminal HIP1 antibody reactivity much more fre-
quently than patients with localized primary tumors (Table 2;
Figure 3; 46% vs. 0%; Po0.005; Pearson’s w2 analysis). This
test in this cohort was 100% specific. No patient with
localized disease tested positive for anti-HIP1 antibodies
in their serum. Hence, a positive test for anti-N-terminal
HIP1 antibody reactivity marked the presence of metastatic
disease. Additionally, a non-significant trend was also
observed (Table 2) between autoantibody presence and
extensive metastatic disease compared with microscopic
and local lymph node metastases (Table 2). In contrast, the
frequent presence of antibodies against the C-terminal HIP1
antigen in patient sera (85% of patients) did not significantly
associate with metastasis as 62% of patients with localized
disease also tested positive for antibodies against the HIP1
C-terminal antigen.
As might be expected, survival after a positive test for the
anti-N-terminal HIP1 antibodies was poor because the
patients were of advanced stage (metastatic disease). In total,
5 out of 10 patients (50%) with metastatic disease and high
antibody reactivity against the HIP1 N terminus (Figure 2;
group 1) were deceased from disease after a 2.5-year
observation period. This contrasts with the fact that 25% (3/
12) of the patients with metastatic disease and negative anti-
N-terminal HIP1 antibody tests were dead at 2.5 years (below
the line in Figure 2; group 2). This was not a significant
survival difference. In contrast to the 25–50% death rate in
Table 1. HIP1 immunostaining of paraffin-fixed MCC
and SCLC tissue
Tumor type 3+ 2+ 1+
No
staining
HIP1
positivity (%)
MCC
Total (n=28) 3 8 14 3 89**
Primary 2 4 9 1 94
Metastatic 1 4 5 2 83*
SCLC
Total (n=12) 0 1 4 7 42
Primary 0 0 3 2 60
Metastatic 0 1 1 5 29
Abbreviations: HIP1, Huntingtin-interacting protein 1; MCC, Merkel cell
carcinoma; SCLC, small-cell lung cancer.
**Significant difference compared with patients with SCLC (Po0.0025,
w2 analysis).
*Significant difference compared with patients with metastatic SCLC
(Po0.025, w2 analysis).
Table 2. Frequency of positive anti-HIP1 (N-terminal) antibody blood test in metastatic MCC
Patient status Positive Negative Frequency Age (years)±SD Male (%)
All MCC patients (n=40) 12 281 0.33 69±12 45
No metastases (n=13) 0 13 0.00 71±12 54
Metastatic disease (n=26) 12 14 0.46** 67±11 42
Extensive metastases 6 3 0.67 72±12 33
Local metastases 3 4 0.38 63±10 50
Micrometastases 3 6 0.33 66±9 44
Abbreviations: HIP1, Huntingtin-interacting protein 1; MCC, Merkel cell carcinoma.
1One patient was lost to follow-up and metastatic status could not be determined.
**Significant difference compared with patients without metastatic disease (Po0.005, w2 analysis).
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the patients with metastatic disease was a 100% survival of
those patients with localized disease and a low anti-N-
terminal HIP1 antibody reactivity (right hand side of Figure 2;
group 3). Two of the original patients in cohorts 1 and 2 were
lost to follow-up, explaining the decrease in patient numbers
between cohorts 1 and 2 in the metastasis (Figure 2) and
subsequent 2.5-year survival data described above.
A disproportionate number of female patients had elevated
anti-HIP1 antibody reactivity in their blood. Approximately
45% of female patients had high anti-N-terminal HIP1
antibody reactivity, whereas only 11% of male patients had
high anti-N-terminal HIP1 antibody reactivity (data not
shown). The positive association between anti-HIP1 anti-
bodies and female gender was significant (Po0.05; Pearson’s
w2 analysis). In fact, when males were excluded,
the association between metastasis and the presence of
N-terminal antibodies tightened (Po0.001). In addition, no
association between the presence of anti-N-terminal HIP1
antibodies and age or tumor size was identified in this elderly
patient population (Table 2).
HIP1 interacts physically and functionally with the c-Kit RTK
MCC tumors express significant levels of several RTKs
(Brunner et al., 2008); however, expression of the receptors
previously reported to interact with HIP1, including EGFR
(Bradley et al., 2007a) and fibroblast growth factor receptor 4
(Wang et al., 2008), were not among those found to be
increased in MCC tissues. Thus, we tested the ability of HIP1
to physically interact with c-Kit, an RTK that is frequently
evaluated in these patients because it is expressed at high
levels in MCC tumors (Figure 1c; Brunner et al., 2008). As
c-Kit is rarely expressed in normal adult tissues other
than progenitors of the hematopoietic system such as
rare hematopoietic stem cells (Bernex et al., 1996),
we coexpressed V5 tagged complementary DNA for c-Kit
along with myc tagged complementary DNA for HIP1 in
human embryonic kidney 293T cells to obtain enough
material for analysis. HIP1 was immunoprecipitated
from the whole-cell lysate using rabbit anti-myc sepharose
beads. Western blot analysis of the immunoprecipitate
showed that c-Kit was specifically co-immunoprecipitated
with HIP1. In the absence of overexpressed HIP1, there was
no co-immunoprecipitation (Figure 3a, left hand panel, lane
1 vs. 2). In addition, the reverse immunoprecipitation with
anti-V5 sepharose beads also demonstrated co-immuno-
precipitation with HIP1 (Figure 3a, right hand panel,
lane 4 vs. 5).
We hypothesized that if this interaction was functionally
related to endocytosis, it may be dependent on activation of
the receptor. Addition of stem cell factor (SCF), the c-Kit
ligand, 1 hour before cell collection for immunoprecipitation
did indeed enhance the detected interaction between c-Kit
and HIP1 (Figure 3a, lanes 3 and 6). Western blot analysis of
whole-cell lysates from these cells showed no differences in
c-Kit expression in those cells treated with SCF as compared
with untreated cells. We also observed an interaction
between endogenous HIP1 and c-Kit in an MCC cell line
(MCC565) when SCF was added to the cell media 1 hour
before cell harvest. This interaction was not observed in the
absence of SCF (Figure 3b). We also examined whether HIP1
overexpression has the ability to inhibit the degradation of the
c-Kit receptor similar to the effect of HIP1 on EGFR and
fibroblast growth factor receptor 4 levels. Indeed, HIP1
stabilized c-Kit following SCF stimulation of starved
and cycloheximide-treated cells. The receptor levels were
significantly higher 1 and 2hours after stimulation when
HIP1 was overexpressed with c-Kit (Figure 3c). These data
together suggest that the interaction of HIP1 with c-Kit is
functionally important.
DISCUSSION
MCC is a rare cancer, for which investigation of the
molecular mechanisms of its cause and maintenance, to
guide the development of better treatment regimens, has
only recently received significant attention. Patients with
MCC have a poor prognosis similar to patients with other
neuroendocrine tumors such as SCLC. In contrast to SCLC
patients (Socinski and Bogart, 2007), MCC patients suffer
from a lack of therapies and prognostic markers (Bichakjian
et al., 2007). In this study, we demonstrate not only that HIP1
is a useful immunohistochemical marker for MCC but also
that autoantibodies against the N terminus of HIP1 in patient
sera predict the presence of metastatic disease. The discovery
of high HIP1 levels in the tumors of MCC patients has led to
the hypothesis that HIP1, which acts as an oncoprotein when
expressed at high levels, contributes to the mechanism(s) of
MCC development, maintenance, or progression. Our data
suggest that overexpression of HIP1 leads to elevated RTK
levels through its prevention of receptor degradation
and therefore may increase pro-growth signals, leading to
transformation of Merkel cells.
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Figure 2. Antibody reactivity against the N-terminal antigen is elevated in
metastatic Merkel cell carcinoma (MCC) patients. Individual dots represent
relative antibody titers from patients with either metastatic MCC or localized
MCC. Members of groups 1–3, defined by test result and whether or not their
disease was metastatic, are enclosed by the boxes. Mean and standard error of
the mean for each data set are indicated by horizontal and vertical lines,
respectively. HIP1, Huntingtin-interacting protein 1.
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The high levels of HIP1 or fragments of HIP1 released from
the cytoplasm of necrotic or dying MCC tumor cells likely
serve as immunogens in MCC patients, leading to the cancer
specificity of a positive anti-HIP1 antibody test (Bradley et al.,
2005). Here, we employed both a different N-terminal HIP1
test antigen and the previously described C-terminal HIP1 test
antigen for anti-HIP1 antibody analysis (Bradley et al., 2005)
and found that antibodies against the N terminus of HIP1 are
present more frequently in patients with metastatic MCC than
in patients with localized MCC. This association was not
found for the C-terminal antigen, as many more patients had
a positive test result, making correlation with prognostic
factors insignificant. Notably, although anti-HIP1-N-terminal
antibodies were associated with metastasis, no other clinical
parameter, such as tumor size, was associated with antibody
test results. As locally treated MCC is often recurrent and can
unpredictably metastasize and become unmanageable (Bi-
chakjian et al., 2007), future prospective studies of this
upgraded anti-HIP1 blood test using both antigens will be
important to execute. These clinical trials will also help to
determine whether the presence of these antibodies serves as
a marker of existing metastatic disease alone or whether
the antibodies are predictive of tumor metastatic potential.
If the presence of HIP1 autoantibodies can serve as a
predictive marker in early disease stages, then positive blood
test results could indicate the need for more aggressive early
adjuvant therapy.
The prognostic results associated with this improved HIP1
N-terminal antigen blood test support re-evaluation of
patients with other metastatic and localized epithelial
cancers for antibodies against the N-terminal HIP1 antigen
compared with patients with localized disease. For example,
as HIP1 overexpression in prostate cancer tumors is asso-
ciated with poor prognosis (Rao et al., 2002), it is possible
that relapsing patients will also have increased anti-
N-terminal HIP1 antibody reactivity like metastatic MCC
patients. As the decision to surgically resect prostate tumors is
often difficult because of potential urological side effects, the
value of a blood test to predict which tumors are likely to
metastasize would be useful. Moreover, a combination test
for both HIP1 N- and C-terminal antibodies may be more
sensitive and specific than either test alone.
The gender-specific association of metastases with the
N-terminal anti-HIP1 antibodies that was found mainly in the
female patients was intriguing. This observation is similar to
the known increased frequency of autoimmune diseases in
women compared with men (Lockshin, 2006). In addition, a
recent report found that in MCC patients female gender
correlated with better survival (Kaae et al., 2010). Perhaps,
the ability to immunologically respond to high HIP1 levels
improves prognosis. For example, in B-cell lymphoid
malignancies, anti-HIP1 reactivity correlated with good
outcome (Bradley et al., 2007b). Of course, future tests of
the prognostic value of antibodies to the HIP1 N-terminal
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antigen will still include men, as this study examined too
few men with metastases (n¼10) to be conclusive. Future
prospective trials will be important to either confirm or refute
these initial gender-specific results.
The mechanisms of how HIP1 transforms cells remain a
subject of investigation. The prevailing hypothesis is that
HIP1 inhibits the degradation of active RTKs during the
process of receptor-mediated endocytosis (Hyun and Ross,
2004) because of the data showing that its overexpression
stabilizes RTKs following receptor activation (Hyun et al.,
2004). For example, cells transformed by HIP1 overexpres-
sion have elevated EGFR levels, and specific EGFR inhibitors
inhibit the transformed phenotype, suggesting that this
receptor stabilization is an essential element of HIP1-
mediated transformation (Rao et al., 2003). Previous reports
have also shown that HIP1 physically interacts with EGFR
(Bradley et al., 2007a) and fibroblast growth factor receptor 4
(Wang et al., 2008). Neither of these receptors is known to be
expressed in MCC, suggesting that the tumorigenic function
of HIP1 in MCC may be mediated through modulation of a
different RTK.
For example, the c-Kit RTK is often overexpressed in MCC
and other tumor types, such as breast tumors, SCLC,
colorectal cancers, and gastrointestinal stromal tumors,
where it is a pharmacological target of imatinib (Su et al.,
2002; Sattler and Salgia, 2004). A recent report has linked
c-Kit overexpression to poor prognosis in MCC (Andea et al.,
2010). The finding here of HIP1’s ability to interact physically
with c-Kit and to increase c-Kit levels provides a plausible
mechanism for how HIP1 might promote tumorigenesis in
MCC. It is less clear, although important to determine, how
high HIP1 levels in MCC might relate to Merkel cell polyoma
virus infection of Merkel cells. If these two abnormalities are
mechanistically linked, i.e., if HIP1 is upregulated by Merkel
cell polyoma virus or vice versa, then targeting the regulator
would be expected to affect the other. This possibility could
be tested in vitro with knockdown of HIP1 or large T antigen
to determine the effect on each other’s expression.
In summary, we report that HIP1 is to our knowledge a
previously unreported marker of MCC, a neuroendocrine
tumor of the skin, and that a blood test for anti-HIP1
antibodies may provide prognostic information. The original
assay (Bradley et al., 2005) was supplemented by use of a
different recombinant HIP1 N-terminal antigen. The findings
with this test will necessitate future studies to determine
whether the distinct anti-HIP1 antibodies are reflective of
metastatic potential of other tumors (prostate, lymphoid, and
brain) expressing high levels of HIP1. Prospective trials that
include a larger number of patients and serial blood samples
will be needed to validate these results to facilitate improved
management of MCC patients. Finally, we report that HIP1
physically interacts with and stabilizes the c-Kit RTK and that
this interaction is modulated by the c-Kit ligand, SCF. Results
of future studies that elucidate all of the RTKs that interact
with HIP1 in MCC, the domains through which these
interactions are mediated, and the effects of these interactions
on transformation and signaling will be enlightening.
Designing drugs for specific inhibition of the interactions
between HIP1 and RTKs may prove therapeutic to many
cancer patients including those afflicted with MCC.
MATERIALS AND METHODS
MCC and SCLC tissue samples
Archived formalin-fixed and paraffin-embedded MCC and SCLC
tissue samples were obtained from the Pathology Department at the
University of Michigan Medical Center. Diagnoses were determined
by CK20, thyroid transcription factor-1, synaptophysin, chromogra-
nin A, morphology, and the site of the primary tumor. TMAs were
generated from 14 of the MCC patient tumors as described
previously (Perrone et al., 2000) and cores were spotted in triplicate.
These patient samples were not linked to clinical data or other
identifying information.
Immunohistochemical staining
Immunohistochemical staining for HIP1 was performed as described
previously (Bradley et al., 2007a) with appropriate negative
(no primary antibody) and positive (glioblastoma) controls. Staining
for Merkel cells in mouse skin was performed using the mouse
monoclonal antibody Ks20.8 (Thermo Scientific, Waltham, MA).
Photomicrographs of the immunohistochemical staining were taken
with a Olympus BX41 microscope (Shinjuka, Tokyo, Japan).
Patients analyzed for serum antibodies against HIP1
The study of patients with MCC and serum levels of anti-HIP1
antibodies was approved by the University of Michigan Internal
Review Board, where written and informed patient consent and
adherence to the Declaration of Helsinki Principles was confirmed.
Serum from 40 clinicopathologically confirmed MCC patients was
collected at the University of Michigan Merkel Cell Carcinoma clinic
in a period of 6 months, ranging from 2007 to 2008. Serum was
aliquoted into 20 ml portions for single use to avoid freeze–thaw
cycles and stored at 801C. The ages, genders, and tumor stages of
these patients are displayed in Table 2.
Preparation of HIP1 antigen
Glutathione S-transferase HIP1 (30 and 50) fusion complementary
DNAs were used to generate C- and N-terminal recombinant
antigens, respectively. The C-terminal antigen has been previously
described (Bradley et al., 2005). The N-terminal antigen was
generated by subcloning an in-frame glutathione S-transferase fusion
protein to the 50 end of the region of HIP1 that terminates at the
internal EcoRI site in the HIP1 nucleotide sequence. The antigen was
produced in bacteria and purified as previously described for the
C-terminal antigen (Bradley et al., 2005).
Test for anti-HIP1 antibodies in MCC patient serum
Immunoblot of patient serum was performed as previously described
(Bradley et al., 2005). The optical density reflective of serum
antibodies bound to the HIP1 antigen was measured using the
ImageJ program (National Institutes of Health, Bethesda, MD), and
measurements were made after subtracting the background density
above and below the HIP1 antigen in each lane. Lanes that had an
optical density of at least 20% of the internal positive control (JMM,
a patient with acute lymphoblastic leukemia from Bradley et al.
(2007b), was tested for the C-terminal antigen and MCC8, a patient
with MCC in this cohort, was tested for the N-terminal antigen) were
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considered positive. From previous studies of mice and humans with
prostate (Bradley et al., 2005) and lymphoid cancers (Bradley et al.,
2007b), a cutoff of more than 20% of a strong standard (internal
positive control) was used to determine if the sera was negative
(o20%) or positive (420%) for reactivity.
Statistics
Data were analyzed using GraphPad Prism 5 statistical software
(GraphPad Software, La Jolla, CA) and ImageJ densitometry analysis
software. Statistical significant values for Tables 1 and 2 were
calculated using Pearson w2 analysis. Statistical significance values in
Figure 3 were calculated using the Student’s t-test.
Miscellaneous
Immunoprecipitation, western blot analysis, and RTK stabilization
assays were performed as described previously (Hyun et al., 2004)
and specific details are also included in Supplementary Materials.
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